Kanaferon Injection contains Iron Sucrose at a concentration of 20 mg/ml and is indicated for the treatment of iron deficiency anemia, particularly in patients with chronic kidney disease undergoing hemodialysis or those who are intolerant or unresponsive to oral iron therapy. The intravenous administration of Iron Sucrose facilitates rapid replenishment of iron stores, promoting effective erythropoiesis and improving hemoglobin levels. Kanaferon Injection is typically administered by slow intravenous injection or infusion under medical supervision, with dosing individualized based on the patient’s iron requirements, hemoglobin concentration, and clinical response. The formulation is designed to minimize the risk of adverse reactions commonly associated with parenteral iron preparations, such as hypersensitivity and hypotension. Prior to administration, patients should be evaluated for iron overload conditions and hypersensitivity to iron sucrose or any component of the formulation. Monitoring of serum ferritin, transferrin saturation, and hemoglobin levels is recommended to guide therapy and avoid iron overload. Adverse effects may include transient hypotension, nausea, or injection site reactions, which are generally mild and self-limiting. Kanaferon Injection should be used with caution in patients with active infections or hepatic impairment. This product provides an effective and well-tolerated option for intravenous iron supplementation in appropriate clinical settings.